Abuse-Deterrent Opioids Effectiveness, Value To Get ICER Review
Executive Summary
Pending arrival of several new products prompts evaluation of class, ICER CSO Dan Ollendorf explains; availability of both abuse-deterrent and non-abuse-deterrent drugs among challenging issues.
You may also be interested in...
Abuse-Deterrent Opioids: FDA Advocates Joint Brand-Generic Development Plan
Despite ‘tension’ between two industries over what is required to show generic is no less abuse-deterrent than innovator opioid, FDA’s Throckmorton suggests they come up with single approach to product development.
Abuse-Deterrent Opioids: FDA Advocates Joint Brand-Generic Development Plan
Despite ‘tension’ between two industries over what is required to show generic is no less abuse-deterrent than innovator opioid, FDA’s Throckmorton suggests they come up with single approach to product development.
Value Vs. Values: ICER’s Review Of Opioid Abuse-Deterrent Formulations
The Institute for Clinical & Economic Review is setting an appropriately broad scope in its review of the abuse-deterrent opioid class. But the project opens up a much larger question of how broadly to define value – and how to weigh non-economic values – in cost-effectiveness reviews.